Edition:
United Kingdom

Curis Inc (CRIS.OQ)

CRIS.OQ on NASDAQ Stock Exchange Global Market

0.50USD
23 Feb 2018
Change (% chg)

$0.00 (+0.28%)
Prev Close
$0.50
Open
$0.50
Day's High
$0.52
Day's Low
$0.47
Volume
228,309
Avg. Vol
298,422
52-wk High
$3.22
52-wk Low
$0.47

Latest Key Developments (Source: Significant Developments)

Curis Inc says Q3 loss per share $0.11
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Curis Inc -:Curis reports third quarter 2017 financial results.Q3 revenue $2.4 million versus I/B/E/S view $2.2 million.Q3 loss per share $0.11.Q3 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Curis Inc - ‍announce Acceptance Of Investigational New Drug (IND) application for CA-4948​.  Full Article

Curis Q2 loss per share $0.09
Thursday, 4 Aug 2016 

Curis Inc : Curis reports second quarter 2016 financial results . Q2 loss per share $0.09 . Q2 revenue $1.7 million versus i/b/e/s view $2.1 million .Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.  Full Article

Curis reports Q1 loss of $0.07 per share
Monday, 9 May 2016 

Curis Inc : Curis reports first quarter 2016 financial results . Q1 loss per share $0.07 . Q1 revenue $1.7 million . Q1 revenue view $2.3 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Curis Announces Initiation Of Phase 1 Trial Of CA-4948

* CURIS ANNOUNCES INITIATION OF PHASE 1 TRIAL OF CA-4948, A SMALL MOLECULE INHIBITOR OF IRAK4 KINASE IN PATIENTS WITH LYMPHOMA Source text for Eikon: Further company coverage: